GALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFondazione del Piemonte per l'Oncologia
About this trial
GALENOS 1 is a prospective observational study designed to explore longitudinal changes in nutritional status and body composition in patients with head and neck squamous cell carcinoma, locally advanced rectal cancer, and lung cancer undergoing standard antineoplastic treatments. The study is the preparatory observational component of the FOR-GALE PREVENTION project, which aims to support the future development of a galenic immunonutrition dietary supplement intended to reduce adverse events and improve treatment compliance
Eligibility criteria
Qualifiers
Written informed consent provided before study procedures
Male or female participants aged 18 years or older
Histological or cytological documentation of head and neck squamous cell carcinoma, locally advanced rectal cancer, or lung cancer
Candidate for standard antineoplastic treatment according to clinical practice
Disqualifiers
Incomplete recovery from surgery before start of antineoplastic treatment
Other additional malignancies progressing or requiring active treatment within the previous 3 years, except localized basal cell carcinoma, localized squamous cell carcinoma of the skin, or cervical carcinoma in situ
Active infection requiring systemic antibiotic therapy Serious or unstable medical conditions, psychiatric disorders, or substance abuse that would interfere with study compliance
Receipt of any live vaccine within 30 days before planned start of study therapy
Trial design
Treatments tested in this trial
- Not listed
Trial groups
110 Participants
are grouped into 3 trial groupsSponsors and collaborators
Source ClinicalTrials.gov